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Abstract
Two large, recently published observational studies demonstate a clear down-trend in the use of radiotherapy (RT)
over the last 15 years, both in the setting of follicular and diffuse large B-cell lymphoma. This change of practice
might have a negative impact on clinical outcome. Even within the context of modern systemic therapy, omission
of RT translates not only into a shorter progression-free survival (PFS), but also into a worse overall survival (OS). RT
should therefore remain standard practice.
This short review is aiming to summarize current guidelines and the best evidence available in the management of
non-Hodgkin’s lymphoma. Potentially practice changing, ongoing trials will be highlighted.
Introduction
In the management of non-Hodgkin’s lymphoma
(NHL), radiotherapy (RT) has been the first treatment
leading to long-lasting remission and even cure for a
number of patients at the beginning of the 20th cen-
tury [1, 2]. More recently, combination chemotherapy
and immuno-chemotherapy with the addition of ri-
tuximab has evolved with increasing efficacy and now
plays a major role in the management of many B-cell
NHLs [3].
RT is a local treatment, and only patients with early
stage disease can be treated with curative intent using
RT as a single modality. RT is currently used as the pri-
mary treatment in early stage, indolent lymphomas. For
localized aggressive lymphomas, RT is often delivered as
consolidation therapy after systemic chemotherapy in a
multimodality therapy approach. For patients with ad-
vanced NHL, indications for the use of RT are less
obvious and the evidence less robust [4].
A decreasing use of consolidative RT after multiagent
chemotherapy has been observed over the last 15 years.
In a recent large retrospective study, two thirds of pa-
tients with early stage diffuse large B-cell lymphoma
(DLBCL) are now treated with (immuno-) chemotherapy
alone; the authors observed a decline in the use of con-
solidation RT from a peak of 47 % in 2000 to a nadir of
32 % in 2012 (p < 0.001) [5]. Omission of radiotherapy
and abandonment of combined-modality approaches in
current clinical practice might not always be fully
evidence-based, and prompted us to perform a short re-
view of the literature.
We conducted a search of MEDLINE using PubMed
in January 2016, dated back to January 1, 2004. The
MeSH search terms included “low-grade lymphoma”
and “high-grade lymphoma” and used the limiting terms
“radiation therapy”, “randomized controlled trials”, and
English language. We further focused our search by ex-
cluding mantle-cell, marginal zone lymphoma and other
rare types of lymphomas. We also reviewed reference
lists of current guidelines; precedence was given to the
National Comprehensive Cancer Network (NCCN) rec-
ommendations and European Society for Medical
Oncology (ESMO) Clinical Practice Guidelines [6–8].
Follicular lymphoma (FL)
FL represents the most common indolent NHL in the
USA and Europe, accounting for an estimated 20-30 %
of all NHL [9]. The genetic hallmark of FL, the trans-
location t(14;18)(q32;q21), results in the constitutive
overexpression of the bcl 2 protein, impairing the nor-
mal germinal centre apoptotic programme [10].
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Initial workup should include an adequate staging
(including bone marrow examination) to ensure pre-
cise definition of the extent of the disease. Recently,
the use of PET imaging - in clinical trials and clinical
practice - has been recommended as the preferred
option for staging and remission assessment of all
FDG-avid NHLs, including follicular lymphoma by an
International Consensus group [11]. In FL, the use of
positron emission tomography (PET) scanning is par-
ticularly useful in patients presenting with early stage
disease to confirm localized disease before initiating
RT [7].
RT remains the current standard of care for patients
with low-grade (grade 1-2), early stage FL (non-bulky
stage I-II), which represent 10-15 % of all FL [7]. Other
options in selected cases include observation, immuno-
therapy (rituximab) and chemotherapy. FL grade 3b is
regarded as an aggressive lymphoma and treated like
DLBCL.
Despite NCCN and ESMO guidelines endorsing RT as
the preferred initial management [6, 7], RT use in pa-
tients with early-stage low-grade FL continues to de-
cline. In the largest retrospective cohort study reported
so far (35,961 patients), use of RT dropped from 37 % in
1999 to 24 % in 2012 (p < 0.0001), correlating with an in-
crease of observation from 34 % to 44 % (p < 0.0001)
over the same period [12]. In this paper, the use of RT
was associated with a significant 12 % absolute improve-
ment in the 5-year and a 14 % absolute improvement in
the10-year overal survival (OS) rate. An identical 14 %
absolute 10-year OS benefit in patients receiving RT was
noted in an older population-based analysis from 1973
through 2004 from the SEER data set [13]. These data
suggest that even within the context of modern systemic
therapy, RT significantly contributes to survival for pa-
tients with early-stage low-grade FL and should remain
standard practice.
These results have been challenged by a retrospective
multicenter observational study (National LymphoCare
Study). In this series, only 111 out of 474 patients
(23.4 %) with stage I FL received RT as single modality
treatment [14]. Excellent outcomes with different treat-
ment approaches were achieved, suggestive of a potential
PFS benefit for systemic therapy plus RT or systemic
therapy plus rituximab over RT alone, but without any
OS difference [15]. However, several flaws make it diffi-
cult to draw any conclusions on treatment choices from
this retrospective analysis. The National LymphoCare
study was not designed to compare different therapeutic
options in early-stage FL, and selection of treatment was
not based on predefined entry criteria [10, 16]. Further-
more, a potential conflict of interest might arise from
the partial funding of this study by pharmaceutic com-
panies (Genentech and Biogen).
The dogma of early-stage, indolent lymphoma as a
pure localized disease (amenable to cure with RT) has to
be challenged, as nearly half of patients with early-stage
FL will relapse within ten years, almost exclusively in
distant non-irradiated areas [17]. It should be noted that
with the increasing integration of PET-CT into initial
management, improved staging accuracy may translate
into improved disease control and survival rates for
early-stage FL, by excluding patients with occult, distant
disease [18]. For the latter, lymphoma remains the lead-
ing cause of death [19].
In this context, rituximab represents an ideal systemic
drug with a low toxicity profile, aiming to eliminate cir-
culating lymphoma cells as well as distant subclinical in-
volvement, and would complement nicely RT, which
targets macroscopic disease only. Furthermore, rituxi-
mab proved as a radiosensitizer in vitro, enhancing
radiation-induced apoptosis and cell growth delay [20].
Prospective studies are therefore urgently needed, to an-
swer the question if single-agent rituximab, rituximab
combined with involved-field radiotherapy (IFRT) (se-
quential and/or concomitant), or even radioimmunother-
apy offers any advantage over IFRT alone [21]. So far, we
are only aware of a single prospective, multicentric phase
II-study (MIR trial, 85 patients) in the field. The treatment
included a first sequence of rituximab (4 weekly cycles;
375 mg/m2 body surface), a four week treatment gap with
a restaging CT / planning CT of the involved region in
week seven, and followed by another block of rituximab (4
weekly cycles) concurrently with an IFRT of 40 Gy for
macroscopic tumor or 30 Gy in case of a complete remis-
sion after rituximab induction [22]. Preliminary results
were presented in abstract form in 2012; the authors
stated that this combined treatment was well tolerated; 2-
year PFS was similar to historical data with large field RT
without the accompanying toxicity and was superior to
historical data of IFRT only [23]. Mature results are pend-
ing, however.
In current practice, we consider that RT should not
be omitted outside clinical trials. For patients with
low-grade, early-stage FL, general dose guidelines are
24-30 Gy and 24-36 Gy according to NCCN and
ESMO recommendations [6, 7].
The British National Lymphoma Investigation (BNLI)
randomized study showed that 24 Gy in 12 fractions was
as effective for local control as 40 Gy in 20 fractions in
terms of overall response and within field progression
[24]. This attractive 24 Gy dose recommendation has
not been universally implemented so far, as the trial pre-
sents some shortcomings, including a greater heterogen-
eity both in terms of histological diagnosis (FL grade 1-2
making only 59 % of the 289 patients with indolent
lymphoma) and in the evaluation of treatment response
(no consequent 3D imaging during follow-up).
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Very low-dose radiotherapy (4 Gy) has been evaluated
in a Dutch phase II study of 109 patients with recurrent
indolent lymphoma (98 cases with FL), with an overall
response rate of 92 %. The subgroup of 67 patients with
complete response (CR) showed a median time to pro-
gression of 25 months and a median time to local pro-
gression of 42 months [25].
To address prospectively the issue of very low-dose
RT, the FORT trial randomized 614 sites (in 548 pa-
tients) to receive either 24 Gy or 4 Gy. Results clearly
showed that 4 Gy was inferior to 24 Gy in terms of time
to local progression (HR of 3.4; 95 % CI: 2.09-5.55; p <
0.001) [26]. The FORT trial has been criticized not only
for presenting similar flares to the previous dosage study
(40 Gy vs 24 Gy) as mentioned above, but also for not
stratifying patients and assessing local response according
to the initial size of lesions; the non-inferiority of the 4 Gy
regimen might not be excluded for smaller FL lesions [27].
To illustrate their point further, the same investigators
highlight the encouraging results achieved with orbital
lymphoma, where the 2x2 Gy schedule appears to be quite
a valuable option, with two retrospective studies reporting
a local PFS of 100 % at 2 years [28, 29].
Taken together, 24 Gy can be considered as the lowest
standard dose for curative treatment of most patients
with low grade, early-stage FL, until a lower dose (that is
in between 4 Gy and 24 Gy) is explored properly [16].
For patients with asymptomatic, low-tumor burden
stage III-IV disease, FL is considered as a chronic dis-
ease; a “watch and wait” strategy is usually recom-
mended. The natural course of disease is characterized
by spontaneous regression in 10-20 % of cases [7]. Sys-
temic treatment (rituximab ± chemotherapy) should only
be initiated when a patient presents with indications for
treatment (Groupe d’Etude des Lymphomes Folliculaires
(GELF) criteria) [6]. Future research protocols will also
integrate second-generation anti-CD20 antibodies (ofa-
tumumab and obinutuzumab), lenalidomide, mTOR in-
hibitors (temsirolimus and everolimus) Bcl-2 or Bruton’s
tyrosine kinase (BTK) inhibitors.
Local palliation with low-dose RT (2x2 Gy) may be
used in selected cases. This treatment regimen provides
effective symptomatic relief for tumor bulk of all sizes,
with an overall response rate of 81 % [30]. Should the
patient progress again locally without significant sys-
temic progression of disease, local treatment with 2x2
Gy can be repeated. This low-dose RT regimen remains
an excellent option in the palliative and relapse setting,
especially for patients with poor performance status, and
should be practiced more frequently [16].
Diffuse large B-cell lymphoma (DLBCL)
The most common type of aggressive B cell lymphoma
is DLBCL, accounting for approximately 30 % of NHLs
diagnosed annually [31]. Gene expression profiling studies
have revealed significant heterogeneity within DLBCL.
Incoroporation of this information into treatment algo-
rithms awaits further investigation [6].
Early-stage DLBCL
Prognosis is very favorable for patients with early-stage
disease with no adverse risk factors (i.e. elevated LDH,
bulky disease, older than 60 years or ECOG performance
status of 2 or more).
For patients with non-bulky (<7.5 cm) early-stage dis-
ease (stage I-II), R-CHOP (3 cycles) + RT, or R-CHOP
(6 cycles) +/- RT is recommended by the NCCN guide-
lines [6]. The ESMO guidelines recommend 6 x R-CHOP
for patients ≤ 60 years of age and 6 x R-CHOP-21 or
6 x R-CHOP-14 plus 2 x R for patients 60-80 years
of age, respectively [8]. Patients with bulky disease
(7.5 cm or larger) may be more effectively treated with
6 cycles R-CHOP + consolidative IFRT. These recommen-
dations are mainly based on SWOG 8736 [32, 33] and the
MabThera International (MInT) trial [34, 35].
When indicated, consolidative RT should be delivered
up to a total dose of 30-36 Gy for patients achieving CR
after chemotherapy plus rituximab, while patients achiev-
ing only partial response (PR) after induction therapy
should receive 40-50 Gy according to NCCN recommen-
dations; ESMO doesn’t provide any general dose guide-
lines for RT [6, 8].
The role of rituximab has been evaluated in the MInT
trial, a randomized phase 3 trial comparing 6 cycles of
CHOP-like chemotherapy to 6 cycles of CHOP-like
chemotherapy plus rituximab. Consolidation RT was in-
cluded for all extranodal sites of disease or any site greater
than 7.5 cm. The trial found a benefit for rituximab-
containing immunochemotherapy with a 6-year PFS rate
of 80.2 % vs 63.9 % (p < 0.001) and a 6-year OS rate of
90 % vs 80 % (p = 0.004).
In the pre-rituximab era, the role for consolidative RT
after chemotherapy was examined in four landmark ran-
domized trials: SWOG 8736, GELA LNH 93-1, ECOG
1484, and GELA LNH 93-4.
In the SWOG 8736 trial, 3 cycles of CHOP followed
by IF-RT were superior to 8 cycles of CHOP alone, both
for PFS (5-year estimated PFS 77 % vs. 64 %; p = 0.03)
and OS (5-year estimated OS 82 % vs 72 %; p = 0.02).
However, 10-year follow-up suggested an increase in late
recurrence in patients assigned combined treatment [33].
Extended survival data with more than 17 years of follow-
up showed similar outcomes, with continuous treatment
failure and without a PFS plateau in either arm [36].
The Groupe d’Etude des Lymphomes de l’Adulte
(GELA) LNH 93-1 evaluated the chemotherapy regimen
ACVBP alone, compared with 3 cycles of CHOP and
IFRT in young patients (≤60 years). The ACVBP
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regimen was associated with a better 5-year event-free
survival (EFS) (82 % vs 74 %, p = 0.001) and 5-year OS
(90 % vs 81 %, p = 0.001) than abbreviated chemotherapy
and IFRT [37]. The intensive chemotherapy ACVBP
regimen has not been widely adopted, owing to concerns
about acute and late toxicities [38].
The Eastern Cooperative Oncology Group (ECOG) ad-
ministered 8 cycles of CHOP to patients with stage I-II
diffuse aggressive lymphoma, and randomized those
achieving complete response by CT (172 patients) be-
tween observation and 30 Gy IFRT. The 6-year disease-
free survival (DFS) was 73 % for low-dose RT versus
56 % for observation (p = 0.05), with no improvement in
OS (87 % vs 73 %, p = 0.24) [39].
The GELA LNH 93-4 trial included elderly patients
(>60 years) with stage I-II aggressive lymphoma. Patients
were randomly assigned between 4 cycles of CHOP
alone, or followed with IFRT. The 5-year estimates of EFS
(64 % vs 61 %, p = 0.6) and OS (68 % vs 72 %, p = 0.5) did
not differ between those receiving combined modality
therapy and chemotherapy alone [40].
Taken together, these prospective trials from the pre-
rituximab era suggest that IFRT might improve local
control for patients with early-stage DLBCL, without
providing an OS advantage. It is likely that as systemic
therapy improves, the impact of IFRT may be further di-
minished [38]. Still, complete omission of consolidative
RT might be detrimental for some patients.
Using the National Cancer Data Base, Vargo et al.
identified 59,255 patients with stages I and II DLBCL
treated with multiagent chemotherapy alone or chemo-
therapy plus consolidative RT between 1998 and 2012
[5]. Median follow-up time was 60 months (interquartile
range: 33-93). Use of combined-modality therapy signifi-
cantly decreased from a peak of 47 % in 2000 to a nadir
of 32 % in 2012 (p < 0.001). Estimated 5-year and 10-
year OS rates were 75 % and 55 % for patients receiving
chemotherapy alone, and 82 % and 64 % for patients re-
ceiving combined modality therapy (p < 0.001). In this
large population-based retrospective trial, patients who
received combined multiagent chemotherapy plus RT
had a significant survival advantage over those treated
with multiagent chemotherapy alone.
Ongoing clinical research is necessary to further estab-
lish the role of combined-modality therapy in early-stage
DLBCL in the context of modern systemic therapies. A
risk-adapted treatment approach might emerge, with the
identification of “PET-negative” patients after initial
rituximab-chemotherapy, who could be spared consoli-
dation RT and attendant toxicities [36].
Advanced stage DLBCL
For patients with advanced stage disease (stage III-IV),
treatment with 6-8 cycles of R-CHOP or more intensive
treatment regimens like R-CHOEP, R-ACVBP or even
treatment regimens including high-dose chemotherapy
are recommended [8]. In selected cases, consolidation
RT to bulky sites may be beneficial. These recommenda-
tions are mainly based on the GELA study (LNH 98-5),
which was performed with elderly patients (60-80 years)
with advanced DLBCL, randomized between 8 cycles of
R-CHOP versus CHOP. At a median follow-up of ten
years, PFS (36.5 % vs 20 %) and OS (43.5 % vs 28 %)
were significantly in favor of R-CHOP [41].
Two randomized trials reported data comparing R-
CHOP-21 with dose-dense R-CHOP-14 [42, 43]. These
studies did not show an improvement in outcome for
the dose-dense therapy over the R-CHOP 21 regimen
[6]. Still, the R-CHOP-14 regimen is commonly used for
the treatment of elderly patients outside clinical trials,
based on the excellent results of the RICOVER-60 trial
[44], the equal toxicity of both regimens, and the consid-
erably shortened 12-week treatment with 6 R-CHOP-14
instead of the 24-week treatment with 8 R-CHOP-21.
Assessment of response is best performed with PET
scan at the end of treatment. Interim PET scans can pro-
duce false positive results. In a prospective study evalu-
ating the significance of interim PET scans after 4 cycles
of R-CHOP-14, only five out of 38 patients with a posi-
tive interim PET scan had a biopsy demonstating persist-
ent disease. No difference in PFS outcome was noticed
between interim PET-positive, biopsy negative patients,
and interim PET-negative patients [45]. Interim PET
scan was also shown to be only of limited prognostic
value in a larger prospective, international single-arm
study (SAKK 38/07), which investigated the prognos-
tic value of PET scan after two cycles of dose-dense
R-CHOP-14 (out of 6 cycles followed by two cycles
of rituximab) for previously untreated DLBCL pa-
tients. Patients with a negative interim PET scan
achieved a complete response in 100 % of cases at
the end of treatment, compared with 71 % for PET-
positive patients. While the two-year event-free sur-
vival (EFS) was significantly shorter for PET-positive
compared with PET-negative patients (48 % v 74 %;
p = 0.004), OS at 2 years was not statistically significant,
by both local and central review of the PET results [46].
Although interim PET scan is not recommended rou-
tinely, the end-of-treatment PET scan is highly predictive
of PFS. Among 88 first-line DLBCL patients treated with
6-8 R-CHOP courses, patients with a negative final PET
scan achieved a 2-year PFS of 83 % vs. 64 % for patients
with a final positive PET scan (p < 0.001) [47].
Once the planned course of R-CHOP to a total of 6-8
cycles is completed, an end-of-treatment PET scan will
be performed 6-8 weeks later. For patients achieving
PET-negative CR, observation is an option with strong
consideration of consolidative RT to initially bulky disease
Zimmermann et al. Radiation Oncology  (2016) 11:110 Page 4 of 10
or skeletal involvement [48]. For patients with PR (after
completion of initial therapy), a rescue treatment with
high-dose chemotherapy and autologous stem cell trans-
plantation (ASCT) might be an option in selected cases.
The German High-Grade Non-Hodgkin’s Lymphoma
Study Group is currently running a prospective, phase III
study for aggressive B-cell lymphoma (UNFOLDER21/14
trial; NCT00278408). Patients are initially randomized to
receive either R-CHOP 21 or R-CHOP-14, with a second
randomization to RT or observation for patients with
extranodal or bulky disease (2 x 2 factorial design). The
two arms without RT to bulky (defined as ≥ 7.5 cm) or
extralymphatic sites were closed because of significant in-
feriority with respect to EFS on the second planned in-
terim analysis with 285 patients, suggesting a benefit of
RT in patients with bulky disease [49]. Final results are
awaited, as they will allow to better define the place of
consolidation RT in the setting of aggressive DLBCL, in
the modern era of rituximab and advanced RT treatment
delivery techniques.
For elderly patients (>60 years of age), an amend-
ment to the RICOVER-60 trial (RICOVER-noRTh)
allowed to prospectively compare two cohorts of pa-
tients with DLBCL [50]. Both cohorts were treated
with 6 x R-CHOP–14 + 2R (R-CHOP administered every
2 weeks plus two additional applications of rituximab) be-
fore receiving either IFRT (36 Gy) or no RT. A multi-
variable per-protocol analysis limited to patients with
bulky disease (i.e. excluding patients receiving unplanned
RT) revealed HRs of 2.7 for EFS (p = 0.011), 4.4 for
PFS (p = 0.001), and 4.3 for OS (p = 0.002) for patients
not receiving consolidative RT. Even if patients were
not randomly allocated to RT, this study provides
strong support for adding RT to sites of bulky disease
for elderly patients (>60 years of age) with aggressive
B-cell lymphoma. As PET imaging was not part of
this trial, it is not known whether RT can be omitted in
patients with initial bulky disease who have a negative
PET scan after completion of immunochemotherapy.
In a retrospective analysis of nine consecutive pro-
spective trials from the German High-Grade Non-
Hodgkin lymphoma Study Group, data from 3840 pa-
tients with newly diagnosed DLBCL were available. The
study focused on the 292 patients (7.6 %) with initial
skeletal involvement. Chemotherapy was delivered in
combination with rituximab in 61 cases (20.9 %) and
without rituximab in 231 cases (79.1 %). The analysis of
the effect of RT was restricted to the 161 patients
achieving PR or CR at the end of (immuno-) chemother-
apy, out of studies where consolidation RT was allowed
(mostly 36 Gy in 1.8-2 Gy per fraction). The 133 patients
who received RT to sites of skeletal involvement had a
significantly better 3-year EFS (75 % vs 36 %; p < 0.001)
than the 28 patients not receiving RT, with a trend
towards a better 3-year OS (86 % vs 71 %; p = 0.064).
These data suggest a benefitial effect of RT in DLBCL
patients with skeletal involvement [51].
For patients with non-CR after R-CHOP treatment,
RT might be viewed more as a salvage treatment than
pure consolidation after chemotherapy. We are cur-
rently mainly left with a large, retrospective study
from 974 patients with advanced DLBCL (treated be-
tween 1980 and 1999) pooled from four different
EORTC studies [52]. Out of these 974 patients, 227
achieved PR after eight cycles of doxorubicin-based
chemotherapy. Salvage treatment strategy included
IFRT (114 patients), second-line chemotherapy (93
patients), autologous stem cell transplantation (ASCT)
or surgery (16 and 4 patients each). In multivariate
analysis, RT was clearly the most significant factor af-
fecting both OS and PFS. This study stems unfortu-
nately from the pre-rituximab and pre-PET scan era,
precluding the implementation of its conclusions in
current management stategy.
In patients with advanced aggressive B cell lymphomas
and partial metabolic response after R-CHOP treatment,
the role of RT to residual disease has to be adressed in
randomized trials, like the currently recruiting OPTI-
MAL > 60 trial for elderly patients (NCT01478542).
Primary mediastinal large B-cell lymphoma (PMBCL)
PMBCL is relatively uncommon, comprising around
3 % of all NHL, and up to 10 % of DLBCL. It most
often presents in young adults, with a median age of
35 [53]. Gene expression profiling is distinct from
other types of DLBCL [54]. In common with nodular
sclerosing Hodgkin lymphoma (HL) in the mediasti-
num, it is thought to originate from transformed
thymic B-cells, and there is an intermediate entity
which lies between these two types, currently termed
mediastinal gray-zone lymphoma [55].
In the absence of randomized trials, optimal first-line
treatment for patients with PBMCL is more controversial
than other types of NHL, especially in the rituximab era
[6]. The recently completed CALGB study (NCT00118209)
comparing R-CHOP versus DA-R-EPOCH will provide
useful information wether any particular chemotherapy
regimen is superior.
The use of consolidation RT for PMBCL has been an
historical standard of care, based upon poor results fol-
lowing chemotherapy alone prior to rituximab; further-
more the very poor outcomes for patients who develop
recurrent disease highlighted the need to maximize cures
at first attempt [56]. Considering the potential long-term
toxicities of mediastinal RT, some investigators have
elected to omit consolidation RT [56, 57]. The ongoing
IELSG-37 study (NCT01599559) is currently evaluating
the important question whether RT can be omitted in
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PMBCL patients, who have become “PET-negative” at the
end of initial rituximab-chemotherapy regimens.
Primary CNS lymphoma (PCNSL)
PCNSL accounts for approximatively 3 % of all primary
CNS tumors. It is an aggressive form of NHL that de-
velops within the brain, spinal cord, eye, or leptomenin-
ges, without evidence of systemic involvement [6].
Ninety percent of non-HIV-associated PCNSL cases are
of the diffuse large B-cell type, characterized by lymph-
oid clustering around small cerebral vessels [58]. The
brain parenchyma is involved in more than 90 % of
cases. Leptomeningeal involvement may occur in up to
30 % of patients. Ocular involvement may develop inde-
pendently in ten to 20 % of patients.
The CHOP regimen induces responses of brief
duration in patients with primary CNS lymphoma. This
inefficacy is probably because the metabolite of cyclo-
phosphamide, phosphoramide mustard, and doxorubicin
are not able to cross the blood–brain barrier [59]. Ritux-
imab has also poor CNS penetration because of its large
size. Methotrexate (MTX) is currently the most effective
single agent in PCNSL. Combining antimetabolites such
as MTX and cytarabine (ara-C) constitute the backbone
of most anti-PCNSL regimens with proven efficacy in
prospective trials [60]. In a phase II study conducted by
the International Extranodal Lymphoma Study Group
(IELSG), 79 patients were assigned to 4 courses of MTX
(3.5 g/m2) alone or combined with ara-C (4 doses of
2 g/m2), in both arms followed by whole-brain irradi-
ation (WBRT). The addition of ara-C resulted in signifi-
cantly improved response (CRR: 46 % vs 18 %; p = 0.006)
and better outcome (3-year OS: 46 % vs 32 %; p = 0.07)
compared with high-dose MTX alone, with manageable
hematologic toxicity and uncommon nonhematologic
side effects [61]. Another study highlighted the import-
ance of ara-C dose, suggesting that 4 doses of 2 g/m2 is
an appropriate choice [62]. Although it was not ad-
dressed in a phase 3 trial, the MTX-ara-C combination
is currently the most commonly used treatment regimen
outside clinical trials.
Methotrexate can also be administered as high-dosed
monotherapy. The superiority of high-dose methotrexate
over RT alone has never been demonstrated in a ran-
domized trial [63]. Although not formally compared in a
randomised trial, results of several studies suggest that
the combination of high-dose methotrexate with RT is
better than RT alone, in terms of increasing the propor-
tion of long-term survivors (5-year survival 20–50 %)
and OS by two to four times (median 30–72 months)
[63]. There has been so far only one large prospective
phase III study comparing consolidation WBRT to ob-
servation alone after high-dose methotrexate [64]. The
unmet primary endpoint for non-inferiority and the high
rate of protocol violations (only 318 out of 551 patients
treated per protocol) prevent unfortunately any reliable
conclusions to be drawn from this study [65].
In current practice, chemotherapy will usually be
followed by consolidation RT (or high-dose chemo-
therapy) as initial treatment to maximize response
and improve outcome; WBRT up to 24-36 Gy is rec-
ommended, without a boost, according to NCCN
guidelines [6]. However, it has to be stressed that
consolidation WBRT is associated with high rates of
neurotoxicity, especially in patients > 60 years of age,
and therefore often omitted. Several small retrospect-
ive series suggest that some elderly patients in CR
after primary chemotherapy could be watchfully ob-
served without OS impairment. To delay WBRT until
relapse appears to be an acceptable strategy consider-
ing the increased risk of disabling neurotoxicity in
these patients [60].
To reduce neurotoxicity, investigators explored reduced-
dose WBRT (23.4 Gy in 13 fractions) for those patients
achieving CR after induction chemotherapy with rituxi-
mab, methotrexate, procarbazine, and vincristine (R-MPV).
Consolidation cytarabine was given after RT [66]. This
phase II study was associated with a 2-year PFS rate of
77 %, median PFS of 7.7 years, and 3-year OS rate of 87 %.
This R-MPV regimen with or without reduced-dose
WBRT is currently tested by the Radiation Therapy Oncol-
ogy Group (RTOG 1114 trial).
Building on the same induction immunochemotherapy
(R-MPV regimen), consolidation WBRT can be replaced
by a novel consolidation high-dose chemotherapy with
thiotepa, busulfan and cyclophosphamide (TBC regimen)
and autologous stem cell transplantation (HDC-ASCT).
This strategy has been tested in a prospective, single-arm,
phase II study (32 patients). Following R-MPV, objective
response rate was 97 %, and 26 (81 %) patients proceeded
with HDC-ASCT. There were 3 treatment-related deaths.
Among all patients (N = 32), with a median follow-up of
survivors of 45 months, 5-year overall survival (OS) and
progression-free survival (PFS) were 81 % and 79 %,
respectively. There was no evidence of neurotoxicity
thus far. As stated by the authors, this intensive treat-
ment should still be considered experimental. More-
over, the R-MPV regimen has not been formally
tested alone, without a consolidation strategy such as
WBRT or HDC-ASCT [67].
Outside clinical trials, outcome of CNS lymphoma re-
mains globally dismal. About one third of patients with
primary CNS lymphoma will present with disease that is
refractory to first-line treatment. Even for patients
achieving initial CR, about half of them will relapse. For
refractory or recurrent disease, there are few treatment
options available, and no established standard of care.
For patients who previously achieved a long-lasting
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response to high-dose methotrextate, retained chemo-
sensitivity might be assumed, and a rechallenge with
methotrexate attempted. Conventional chemotherapy
might be proposed as well. For selected patients, specific
salvage therapies might be explored, including high-dose
chemotherapy and ASCT [68], or stereotactic radiosur-
gery [69].
New RT standards should translate into reduced toxicity
Historically, RT has been associated with significant risks
of late toxicities and second malignancies in long-term
survivors; relevant data are mostly derived from retro-
spective HL series [70–72].
The French-United Kingdom study of 4122 5-year sur-
vivors of various childhood cancers between 1942 and
1986 (median follow-up: 26 years) found that the aver-
age dose of radiation to the heart was linearly associated
with the risk of cardiac mortality, with the incidence in-
creasing by 60 % for every 1-Gy increase in mediastinal
radiation dose [73, 74]. In a similar north-american co-
hort study restricted to female participants who had re-
ceived chest irradiation for their childhood cancer
diagnosis (RT treatment between 1970 and 1986), the
cumulative incidence of breast cancer by age 50 years
was 35 % among HL survivors [75]. At this point, it has
to be stressed that these late-toxicity figures apply to pa-
tients treated for childhood cancers with ancient tech-
niques, and cannot be directly extrapolated to mostly
adult patients treated in these days with modern RT.
Different strategies have been implemented to reduce
RT toxicities. As normal tissue complication rate is a
function of dose and volume, RT therapeutic ratio should
improve both with lower treatment doses and smaller tar-
get volumes. For NHL, there is now increasing evidence
that tradional doses were higher than necessary for disease
control; some investigators recommend now no more
than 30 Gy for aggressive NHL or 24 Gy for indolent
lymphomas [76].
Regarding target volumes for aggressive NHL, optimal
imaging allowed to evolve from IFRT (encompassing the
pre-chemotherapy involved node chains, based on ana-
tomical landmarks) to involved site RT (ISRT) (target
volumes reduced to cover the pre-chemotherapy in-
volved nodes only) [3]. Such a strategy is based on the
assumption that chemotherapy already eradicated adja-
cent or regional microscopic disease and ISRT targets
the identifiable pre-chemotherapy disease. Clinical judg-
ment in conjunction with the best available imaging is
used to contour a clinical target volume (CTV) that will
accommodate the uncertainties in defining the preche-
motherapy gross tumor volume (GTV) in each individ-
ual case. In the situation where pre-chemotherapy
imaging cannot be fused with the post-chemotherapy
planning CT scan, allowances should be made for the
uncertainty of the contouring and differences in posi-
tioning by including a larger volume in the CTV [3].
The proposed reduced late toxicity with involved-site
or involved-node RT (INRT) is yet unproven; in the ab-
sence of recent long-term toxicity data, dose–volume
metrics of organs at risk (OAR) will provide a surrogate
measure of toxicity risk. In an Australian study compar-
ing IFRT with INRT using conventional technique
(parallel-opposed anterior and posterior photon beams),
INRT allowed to reduce the proportion of tissue receiv-
ing higher RT doses (V95%) by a factor of 1.9. Regarding
major organs at risk, the greatest benefit was seen when
analyzing the dose received by 50 % of these organs
(D50), which was reduced by half for the heart and the
lungs. Keeping now the same INRT target volume and
comparing between conventional technique and volu-
metic modulated arc therapy (VMAT), VMAT resulted
in further relative reductions in cardiac dose, but with-
out improvement in coronary artery dose-volume met-
rics, and at the expense of increased low-dose exposure
to lungs [77].
A larger retrospective study (150 patients, 73 % with
HL and 27 % with NHL) evaluated recently the risk of
radiation pneumonitis (RP) after mediastinal RT with in-
tensity modulated radiotherapy (IMRT) [78]. The overall
incidence of any RP (RTOG grades 1-3) was 14 % among
the entire group. However, patients who received salvage
chemotherapy or transplantation for relapsed or refrac-
tory disease were at greater risk: the incidence of RP
among those patients was 25 % versus 10 % among those
who received consolidative RT only for newly diagnosed
disease. In both groups, half patients developing pneu-
monitis required a steroid course (RTOG grade 3).
Interestingly, disease bulk, history of smoking, pre-RT
pulmonary function test values, and history of bleomycin
toxicity did not predict RP. Regarding dosimetric factors,
while the V20 (irradiated volume receiving ≥ 20 Gy)
predicted RP risk, the volume of lung receiving lower
doses of radiation, especially V5 (irradiated volume
receiving ≥ 5 Gy), was the most powerful predictor of
RP. If IMRT allows for a better conformality of the
higher doses of radiation, these results are achieved at
the costs of delivering a low-dose bath to large vol-
umes of lung, leading obviously to a clinically mean-
ingful lung injury. The risk of RP approaches 35 %,
when >55 % of the total lung receives 5 Gy in the
treatment of HL or NHL with IMRT.
Different IMRT and VMAT refinements have been re-
cently described, to optimize dose delivery and better
spare OAR. Traditional IMRT beam arrangements in-
volving 9 fixed and equally distributed beams produce a
low-dose bath to the all surrounding critical organs; RT
planning should therefore not be automated, and beam
angles should be carefully selected on an individual
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basis, leading for example to a 5-beam anterior-posterior
weighted “butterfly” coplanar beam arrangement [79]. A
single arc VMAT plan can also be replaced with a more
sophisticated three-arcs VMAT (“butterfly” VMAT), with
two anterior and posterior coplanar arcs of 60°, comple-
mented with 1 no-coplanar arc of 60° [80].
Another possibility to further reduce the target volume
and thus the irradiated volume is the use of gating tech-
niques such as deep-inspiration breath-hold. Combined
with IMRT, it can greatly reduce radiation exposure of
the coronary arteries, heart, and lungs in patients with
mediastinal HL [81]. Despite the obvious advantage to
reduce side effects related to the heart and the coronary
arteries, an open question is the impact of intensity
modulation techniques on the incidence of second ma-
lignancies. While the application of VMAT techniques
can result in better dose spearing of the thyroid gland,
the heart and the coronary ostia, deep-inspiration
VMAT was actually shown to be inferior to classical par-
allel opposed treatment techniques with regard to sec-
ond cancer induction; VMAT can increase for example
the cumulative absolute risk of breast cancer induction
by 100 %. VMAT should therefore be cautiously imple-
mented in clinical practice [82].
Last, proton therapy may offer significant and clinic-
ally relevant advantages to spare important OAR’s, and
has been endorsed by NCCN as an appropriate treat-
ment modality for NHL [6]. While several published
studies have evaluated the use of proton therapy for HL,
data regarding patients treated with proton therapy for
NHL are scarce. Early outcomes appear favorable, but
longer follow-up is needed before drawing any definitive
conclusions [83].
Conclusions
NHLs exhibit both high chemosensitivity and radiosensi-
tivity. The excellent response rates achieved over the last
15 years with R-CHOP treatments in aggressive lymph-
omas, and with rituximab alone or in combination with
chemotherapy in indolent lympomas have lead to the
premise that RT might be obsolete, causing unnecessary
toxicities without impacting favorably on outcome. Two
large observational studies in FL and DLBCL demonstrate
a clear trend towards RT-free regimens in the most recent
years. However, abandonment of RT in favor of (chemo-)
immunotherapy alone might negatively affect patient OS.
Omitting RT in the treatment of NHLs should not be con-
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